US corporation Johnson & Johnson announced the testing of a vaccine against Ebola virus on humans. According to the company, which, together with the Danish Bavarian Nordic plans before the end of the month to complete testing, in April on the market may appear 400 thousand doses of vaccine. According to forecasts, this year will be able to produce 2 million doses of the drug with a possible increase in production capacity to 5 million doses. Due to this news, we expect the stock price increase, but the effect will be short-term in connection with a broad diversification of the company's business and a relatively low portion of the revenues from the sale of the vaccine. According to our estimates the company's shares may decrease by 10-15% in the medium term.